Trademarkia Logo

Canada

C$
INOZYME
APPROVED

on 3 Feb 2025

Last Applicant/ Owned by

Inozyme Pharma, Inc.

321 Summer Street, Suite 400Boston MA 02210

US

Serial Number

2147760 filed on 29th Jun 2021

Correspondent Address

MOFFAT & CO.

P.O. Box 2088, Station DOttawa

ONTARIO

CA

K1P5W3

INOZYME

Trademark usage description

pharmaceutical preparations for the diagnosis and therapeutic treatment of bone and kidney diseases and disorders, tissue diseases in the nature of ri Read More

Classification Information


Class [005]
Pharmaceutical preparations for the diagnosis and therapeutic treatment of bone and kidney diseases and disorders, tissue diseases in the nature of rickets, abnormal mineralization of vessels, intimal proliferation, chronic kidney disease (CKD), and skin calcification, diseases of abnormal mineralization and calcification, diseases of the circulatory system and diseases caused by inborn errors of metabolism in the nature of ENPP1 deficiency (GACI type I/ARHR2), ABCC6 deficiency (GACI type II, PXE), hypopyrophosphatemia, and diseases caused by abnormal intimal proliferation, none of the aforesaid pharmaceuticals for use in the treatment of Pompe Disease.


Classification kind code

11

Mark Details


Serial Number

2147760

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 22
on 28th Feb 2023
Search Recorded
Submitted for opposition 20
on 28th Feb 2023
Examiner's First Report
Submitted for opposition 256
on 19th Sept 2022
Notification of Possible Opposition Sent
Submitted for opposition 231
on 10th Mar 2022
Limitation
Submitted for opposition 48
on 26th Jan 2022
Agent Changed
Submitted for opposition 257
on 18th Nov 2021
Designation Notification - Madrid Protocol
Submitted for opposition 1
on 17th Nov 2021
Created
Submitted for opposition 31
on 17th Nov 2021
Formalized
Submitted for opposition 30
on 29th Jun 2021
Filed
Submitted for opposition 228
on 29th Jun 2021
International Registration